首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.
【24h】

The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.

机译:癌胚抗原耀斑对接受一线化疗的晚期大肠癌患者的影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Carcinoembryonic antigen (CEA) flare may have a favourable response to chemotherapy, but its impact on survival is unknown. This study aimed to evaluate the incidence of CEA flare and its impact on objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). PATIENTS AND METHODS: Patients with histologically proven advanced colorectal cancer undergoing first-line chemotherapy with three or more serial CEA measurements (one at baseline and two or more during treatment) were included. Patients were grouped according to CEA kinetic as flare (F), decreasing CEA, normal baseline CEA, stable CEA and increasing CEA (I). RESULTS: From January 2000 to February 2008, 837 patients were screened of whom 670 were eligible. CEA flare occurred in 78 (11.6%) patients. On multivariate analysis, compared with patients with increasing CEA, patients with CEA flare had a significantly better ORR [I versus F: 11% versus 73%; risk ratio (RR): 27.96; 95% confidence interval (CI): 9.55-81.88; P < 0.001], PFS (median 3.1 versus 8.3 months; RR: 0.38; 95% CI: 0.26-0.56; P < 0.001) and OS (median 10.9 versus 17.7 months; RR: 0.53; 95% CI: 0.34-0.82; P < 0.001). CONCLUSIONS: Compared with patients with rising CEA, flare was an independent favourable predictive and prognostic factor for tumour response and survival.
机译:背景:癌胚抗原(CEA)耀斑可能对化疗有良好的反应,但其对生存的影响尚不清楚。这项研究旨在评估CEA爆发的发生率及其对客观反应率(ORR),无进展生存期(PFS)和总体生存期(OS)的影响。患者和方法:包括经组织学证实为晚期大肠癌的患者,接受一线化疗并进行三项或多项连续CEA测量(基线时一项,治疗期间两项或以上)。根据CEA动力学将患者分组为耀斑(F),CEA减少,基线CEA正常,稳定的CEA和增加的CEA(I)。结果:从2000年1月至2008年2月,筛查了837例患者,其中670例符合条件。 CEA发作发生在78名(11.6%)患者中。在多变量分析中,与CEA增高的患者相比,CEA耀斑患者的ORR明显更好[I vs F:11%vs 73%; I = F:11%vs。风险比(RR):27.96; 95%置信区间(CI):9.55-81.88; P <0.001],PFS(中位数3.1与8.3个月; RR:0.38; 95%CI:0.26-0.56; P <0.001)和OS(中位数10.9与17.7个月; RR:0.53; 95%CI:0.34-0.82; P <0.001)。 P <0.001)。结论:与CEA升高的患者相比,耀斑是肿瘤反应和生存的独立有利的预测和预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号